Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Knocking out genes completely and exclusively in Natural Killer cells

Our immune systems contain three fundamentally different types of cell: B-cells, T-cells and the mysteriously named Natural Killer cells (NK cells), which are known to be involved in killing tumour cells and other infected cells. Experiments to investigate the function of NK cells have proven difficult to interpret because the interactions between the various components of the immune system make it almost impossible to isolate effects of individual cell types.

23 Feb 2011

New study: Cannabis ingredient can improve appetites and sense of taste in cancer patients

The active ingredient in cannabis can improve the appetites and sense of taste in cancer patients, according to a new study published online in the cancer journal, Annals of Oncology today.

23 Feb 2011

Cerasome filled molecular-sized bubbles to target liver cancer cells

Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.

23 Feb 2011

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

23 Feb 2011

Mechanism of cancer treatment related to infertility in women

Chemotherapeutic agents, used in cancer treatment, destroy not only cancer cells but also healthy cells, thus affecting germ cells as well. Consequently, after surviving cancer many female patients are confronted with the diagnosis: infertility. For a long time a relationship between infertility and chemotherapeutic agents has been assumed, but until now, the exact mechanism was not known.

23 Feb 2011

New nanoparticle can help develop vaccines against HIV, malaria

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

23 Feb 2011

Researchers discover biological pathway that alters normal cells into aggressive tumors

A biological pathway that transforms normal cells into aggressive tumors has been discovered by researchers at Cleveland Clinic's Lerner Research Institute.

23 Feb 2011

Cancer-causing retrovirus prolongs survival of host cells

A cancer-causing retrovirus exploits key proteins in its host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and Ohio State's College of Veterinary Medicine.

23 Feb 2011

Breakthrough in Huntington's disease may give patients hope for cure

A huge leap forward in understanding Huntington's disease may give patients hope for a cure.

23 Feb 2011

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

A University of Missouri researcher believes there could be a new drug compound that could kill breast cancer cells. The compound might also help with controlling cholesterol.

23 Feb 2011

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Vical Incorporated announced today that the company has extended its relationship with the U.S. Naval Medical Research Center to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

22 Feb 2011

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin(r) program, currently under evaluation for the treatment of cancer.

22 Feb 2011

MedTrust, Avantra collaborate to develop molecular diagnostic assay for cancer care

MedTrust Online and Avantra Biosciences announced today a novel collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx multiplex immunoassay system.

22 Feb 2011

New technique allows early identification of metastasis in women with breast cancer

A quarter of all women who suffer from breast cancer are at risk of metastasis - a recurrence of the cancer. In recent years, researchers at Lund University, Sweden, have developed a technique that can identify in advance which patients belong to this risk group.

22 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.

22 Feb 2011

Protein News and Research

Further Reading

Knocking out genes completely and exclusively in Natural Killer cells

New study: Cannabis ingredient can improve appetites and sense of taste in cancer patients

Cerasome filled molecular-sized bubbles to target liver cancer cells

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Mechanism of cancer treatment related to infertility in women

New nanoparticle can help develop vaccines against HIV, malaria

Researchers discover biological pathway that alters normal cells into aggressive tumors

Cancer-causing retrovirus prolongs survival of host cells

Breakthrough in Huntington's disease may give patients hope for cure

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

MedTrust, Avantra collaborate to develop molecular diagnostic assay for cancer care

New technique allows early identification of metastasis in women with breast cancer

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

New study: Rapamycin reverses cardiac muscle damage in LEOPARD syndrome mouse model

Studies identify protein that drives inflammation in pancreatic, breast tumors

Mouse model could help develop new classes of antidepressant drugs

A guide to advancing biotherapeutic research eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo